logo

AURA

Aura Biosciences·NASDAQ
--
--(--)
--
--(--)
2.68 / 10
Underperform

Fundamental strength is rated 2.7/10, indicating challenges. Key positives include strong Profit-MV (0.4634) and Cash-MV ( -0.0673) values, but these are offset by sub-par Revenue-MV (-0.2574) and Gross Profit Margin (36.70%). Inventory turnover is high at 47.85, yet other asset-turnover metrics and the PB-ROE factor (0.5830) remain problematic, warranting a guarded stance.

Fundamental(2.68)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.63%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.34%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.82%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight15.91%
1M Return7.79%
PB-ROE
Value0.58
Score0/3
Weight7.26%
1M Return3.56%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.86%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.36%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight36.29%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight15.93%
1M Return7.73%
Net profit / Total profit (%)
Value100.12
Score2/3
Weight2.25%
1M Return1.28%
Is AURA fundamentally strong?
  • AURA scores 2.68/10 on fundamentals and holds a Premium valuation at present. Backed by its -52.25% ROE, 0.00% net margin, -3.51 P/E ratio, 2.27 P/B ratio, and -10.40% earnings growth, these metrics solidify its Underperform investment rating.